Aim: Bone marrow-mesenchymal stem cells (BM-MSCs) possess immunomodulatory properties in the brain. However, it remains unclear whether intravenously transplanted BM-MSCs have a neuromodulator effect on the activation of microglias after ischemic stroke. This study aimed to investigate the immunomodulatory effect of BM-MSCs on the regulation of brain microglial inactivation during the acute phase of stroke.
Introduction
Bone marrow mesenchymal stem cells (BM-MSCs) are adult nonhematopoietic cells frequently used for cellular therapies due to their pluripotent capacity (Wei et al., 2013) . Increasing evidence has suggested that transplantation of BM-MSCs significantly reduce ischemiainduced histological and motor impairment in animal models of ischemic stroke (Okazaki et al., 2008; Xin et al., 2013; Yang et al., 2014; Zheng et al., 2010) . BM-MSCs are capable of passing through the bloodbrain barrier (BBB) (Hill et al., 2004) and localizing to the damaged tissue in an ischemic stroke rat (Hill et al., 2004; Kopen et al., 1999) . The benefits of BM-MSC transplantation on ischemic stroke have been demonstrated in both animal model (Bao et al., 2011; Ding et al., 2011; Liu et al., 2011; Liu et al., 2008; Bao et al., 2011; Ding et al., 2011; Liu et al., 2011; Liu et al., 2008) and patients (Battistella et al., 2011; Lee et al., 2010; Moniche et al., 2012) . In addition to their pluripotent https://doi.org/10.1016/j.brainresbull.2019.10.001 Received 15 May 2019; Received in revised form 10 September 2019; Accepted 1 October 2019 potential, immunomodulatory properties of BM-MSCs have been demonstrated in numerous reports (Castro-Manrreza et al., 2014; Luan et al., 2013) . For example, BM-MSCs have regulatory effects on lymphocyte activation, proliferation and cytokine secretion (Castro-Manrreza et al., 2014; Luan et al., 2013) . Wang et al. (Wang et al., 2014) have reported that intravenous BM-MSC transplantation can significantly increase regulatory T cells and reduce infiltration of gamma delta T cells, indicating in vivo immunomodulatory properties of BM-MSC .
Microglias constitute 15% of the total glial cells in the human brain (Kim et al., 2016) and are the major contributors to postinjury inflammation after cerebral ischemia (Taylor and Sansing, 2013) . Accumulating evidence has shown that activated microglias contribute to the inflammatory cascade and further propagate cell death beyond the initial ischemic region (Cherry et al., 2014; Perego et al., 2013) . Furthermore, it has been shown that inhibition of microglial migration can improve functional outcomes in MCAO rats (Huang et al., 2017; Luo and Chen, 2012) . The microglias in the peri-infarct area are varied in size and shape in the ischemic brain of rats; some are hypertrophied and similar to macrophages (Luo and Chen, 2012; Zanier et al., 2014) .
CD200 is a transmembrane surface glycoprotein with a broad expression pattern and has been suggested to be a marker of native hMSC population (Pietila et al., 2012) . CD200 can bind to its receptor, CD200 receptor (CD200R), to suppress the activity of many immune cells, especially macrophages (Zanier et al., 2014) . The CD200R is expressed only on the myeloid lineage cells (He et al., 2016) , including microglia. Previous studies have shown that CD200-CD200R axis is involved in the down-regulation of microglias activation (Zanier et al., 2014; Li et al., 2012) .
Zanieret al. (Zanier et al., 2014) have shown that BM-MSCs are able to counteract the pro-inflammatory response of primary murine microglias in vitro (Zanier et al., 2014; He et al., 2016; Yan et al., 2013) . Intracerebroventricular infusion of BM-MSCs provokes protective M2 microglia polarization and thus promotes neurogenesis and tissue repair in trauma brain (Zanier et al., 2014; He et al., 2016; Yan et al., 2013) . This finding suggests that the immunomodulatory properties of BM-MSCs are involved in microglial modulation in the brain. However, it remains unclear whether intravenous transplantation of BM-MSCs has a neuromodulatory effect on the activation of microglias following ischemic stroke. Therefore, the purpose of this study was to investigate the immunomodulatory properties of BM-MSCs in the regulation of brain microglial inactivation in the acute phase of stroke of rats.
Materials and methods

Isolation, culture, and labeling of BM-MSCs
The rat BM-MSCs were isolated from the tibia and fibula of Sprague-Dawley rats (weighing 50-100 g, purchased from the Guangdong Medical Laboratory Animal Center) as previously described (He et al., 2016; Li et al., 2012; Yang et al., 2015) . In brief, the rats were euthanized, and the tibia and fibula were collected. The marrow cavities were repeatedly flushed with 10 mL of L-Dulbecco's modified Eagle's medium (DMEM)/F12 (Invitrogen, Carlsbad, CA, USA) to obtain the cell suspension. After washing with phosphate-buffered saline (PBS), the cells were suspended with 6-8 mL of L-DMEM/F12 medium containing 10% fetal bovine serum (FBS) (Invitrogen) and seeded in the 75-cm2 flask. The cells were passaged at 90% confluence. The cells at passage 3 (P3) were characterized by immunostaining with antibodies specific for the surface markers CD29+, CD44+, CD31−, and CD45-. BM-MSCs at P3 were used for CD200 immunofluorescence by incubated with rabbit anti-CD200 (1:100; Abcam, Cambridge, MA, USA) and FITC-conjugated anti-rabbit IgG (1:50; Merck Millipore, USA).
BM-MSC neural induction
For neural induction, sub confluent BM-MSCs were treated with 5 μM forskolin (Sigma), 125 μM 3-isobutyl-1-methylxanthine (Sigma), 10 μM β-mercaptoethanol in NDiff® 227 medium (Kakara, Shiga Prefecture, Japan) supplemented with 20 ng bFGFm (Thermo Fish Scientific, Waltham, MA, USA) for 24 h (Li et al., 2012) . After neural induction, cells were subjected to immunofluorescence staining for CD200 and NeuN with rabbit anti-CD200 (1:100; Abcam, Cambridge, MA, USA) with FITC-conjugated anti-rabbit IgG (1:50; Merck Millipore, USA) and mouse anti-NeuN (1:3000; Merck Millipore, Billerica, MA, USA) with Cy3-conjugated anti-mouse IgG (1:100; Merck Millipore, Billerica, MA, USA, AP124C).
Primary cortical microglias culture and immunofluorescence staining
Primary cortical microglias were harvested from 2-day-old postnatal Sprague-Dawley rat as described previously (Li et al., 2012; Yan et al., 2013; Matsumoto et al., 2007) . The cortices were carefully dissected from the whole brain, the meninges were removed, and cortical tissue was homogenized in L15 media (SH30525.01, HyClone, Logan, UT). Tissue homogenate was centrifuged at 190 g, 4°C for 10 min and then resuspended in DMEM: F12 (11320082, GIBCO, California, USA) supplemented with 10% FBS and 1% penicillin/streptomycin. Mixed glial cultures were incubated at 37°C with 5% CO2. After 7-10 days, the mixed glial cultures were shaken at 100 rpm, 37°C for 1 h to detach and collect primary cortical microglia.
For co-culture, BM-MSCs were added to the mixed glia at a ratio of 1:1 (1.0 × 10 4 microglias and 1.0 × 104 BM-MSCs per well) for 12 h, followed by LPS (100 ng/mL; Alexis Biochemical, UK) treatment for an additional 12 h. After LPS exposure for 12 h, microglias were fixed with 4% paraformaldehyde for 10 min, and then subjected to immunofluorescence staining for iNOS and IBA-1. Primary mouse iNOS antibodies (1:100; Abcam, Cambridge, MA, USA), rabbit IBA-1 (1:100; Abcam, Cambridge, MA, USA) and secondary antibodies Cy3-conjugated anti-mouse IgG (1:100; Merck Millipore, Billerica, MA, USA, AP124C) and FITC-conjugated anti-rabbit IgG (1:100, Merck Millipore, USA) were all used for immunofluorescence staining.
The rat model of middle cerebral artery occlusion (MCAO)
Male adult Sprague-Dawley rats aged 8 weeks (weighted 250-300 g) were purchased from the Guangdong Medical Laboratory Animal Center. The rat model of middle cerebral artery occlusion (MCAO) was established as previously described (Yan et al., 2013; Yang et al., 2015; Matchett et al., 2007) . Briefly, rats were anesthetized, and the right common carotid artery, external carotid artery, internal carotid artery and vagus nerve were separated. MCAO was achieved by insertion of a nylon monofilament in the middle cerebral artery to block blood flow. After ischemic induction, animals were randomly divided into three groups: 1) control group; 2) transplant + PBS group;3) transplant + CD200RAb group. Longa Score Scale was used to assess the neurological behaviors of rats. Only the rats had the Longa Score of 2 or 3 were used in the following experiments. The mortality rate after modeling was 18%. All protocols in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of Guangzhou Medical University.
Intravenous transplantation of BM-MSCs
Transplantation of BM-MSCs was carried out as previously described (He et al., 2016; Li et al., 2012; Yang et al., 2015) . A total of five batches of BM-MSCs were used in this study, and the transplant experiments were primarily repeated with different batches of cells. In brief, P3 BM-MSCs were labeled with the cell tracker marker CM-DiI fluorescent dye (2 μg/mL, Invitrogen, USA) by incubation at 37°C for 5 min and then at 4°C for 15 min. CM-DiI stained BM-MSCs (1 × 106 cells in 200 μL) were transplanted into rat through the tail vein at 12 h after MCAO, and PBS (vehicle) was injected through the tail vein in the control group.
Injection of CD200 receptor 1 (CD200R1) antibody
For injection of CD200R1 antibody, 5 μL CD200R1 antibody (2 μg/ μL AF2554, R&D, NE, Minneapolis, USA) diluted in sterilized water was injected into the peri-infarct area of the rat brain (AP 0.00 mm from bregma, L 1.40 mm, DV 2.0 mm) at 3 h prior to intravenous BM-MSCs transplantation. In the transplant-PBS animals, 5 μL PBS was injected in the same peri-infarct area of the rat brain. The first 0.5 μL CD200R1 antibody was injected from DV 2.0 mm, and every subsequent 0.5 μL CD200R1 antibody was injected after raising the microsyringes by 0.2 mm, until a total 5 μL was sequentially injected. This method can minimize the mechanical damage of the injection in the peri-infarct area.
TTC (2,3,5-triphenyltetrazolium hydrochloride) staining
Seven days after transplantation, the rat was sacrificed, and the brain was immediately collected and placed into a brain slice mold, followed by freezing at −20°C for 20 min. The serial 2 mm-thick slices were then incubated in 0.05% TTC solution (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in the dark for 30 min, followed by fixation with 4% paraformaldehyde for 10-30 min. The stained brain was photographed by a Leica S6D camera (Leica Microsystems Ltd., Wetzlar, Germany). The volume of the infarct area was calculated with Image-Pro Plus 6.0 software (Media Cybernetics Inc., Bethesda, MD, USA). The infarct zone percentage was determined by the following equation: total area of infarct zone / total area of cerebral hemisphere in the affected side × 100%. The number of animals used for TTC staining was n = 5for each group.
Tissue processing for histology
Brain tissue was collected and prepared for histological analysis as previously described (Yan et al., 2013; Yang et al., 2015; Matchett et al., 2007) . Briefly, the animals were anesthetized with abdominal injection of 1% sodium pentobarbital (50 mg/kg) (Najar et al., 2012) and perfused transcardially with 4% paraformaldehyde. The rat brains were removed and submerged in 4% paraformaldehyde (PFA; pH 7.4) at 4°C for 4 h. Four-micrometer-thick serial sections were sliced from the brain at a distance between 1.6 and −0.2 mm from the anterior fontanelle. The number of animals used for histology staining was n = 6 for each group.
Immunofluorescence staining
Immunofluorescence staining was performed as previous procedure (Matsumoto et al., 2007; Sierra et al., 2014) . In brief, the sections were incubated with primary antibodies against IBA-1 (1:100; Abcam, Cambridge, MA, USA), followed by FITC-conjugated anti-mouse IgG (1:100, Merck Millipore, USA). For immunofluorescence staining for CD200, the slide was incubated with rabbit anti-CD200 (1:500; Abcam, Cambridge, MA, USA) and FITC conjugated anti-rabbit IgG (1:100, Merck Millipore, USA). For double immunofluorescence staining for CD200 and mouse anti-NeuN, slide was stained with primary antibodies for CD200 (1:500; Abcam, Cambridge, MA, USA) and mouse anti-NeuN (1:1000, Merck Millipore, Billerica, MA, USA), followed by incubation in a mixture of both Cy3-conjugated donkey anti-mouse IgG (1:500; Jackson ImmunoResearch) and FITC-conjugated anti-rabbit IgG (1:100, Merck Millipore, USA). Immunofluorescence was observed with a confocal microscope (Leica SP8 Microsystems, Wetzlar, Hessen, Germany).
TUNEL staining
Neuron apoptosis in traumatic and ischemic lesions was detected by TUNEL staining using a Roche in situ Cell Death Detection Kit AP (ROCHE, USA) (Matchett et al., 2007; Shrivastava et al., 2012) . The sections were washed twice in PBS for 5 min and incubated for 50 μL TUNEL reaction mixture for 60 min at 37°C. The samples were analyzed by measuring the immunofluorescence at 515-565 nm. The sections were incubated with converter-AP for 30 min at room temperature. After TUNEL staining, the sections were observed under a light microscope. TUNEL-positive cell numbers in the peri-infarct and CA1 regions were calculated as the mean cell numbers in a randomly selected field, with ocular lens magnification of 10 and objective lens magnification of 40.
Western blot
At 2 days and 3 days post-transplantation, peri-infarct cerebral cortex from the affected side were lysed and homogenized in 200 mL of the lysis buffer of radioimmunoprecipitation assay (Beyotime, Beijing, P. R. China). The lysate was centrifuged at 15,000 g for 10 min and the supernatant was collected. Equal amount of protein extract was electrophoresed by 15% sodium dodecyl sulfate (SDS)/polyacrylamide gel electrophoresis (PAGE) and transferred onto polyvinyl difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Antibodies against CD200 (1:700, Abcam, Cambridge, MA, USA), IBA-1 (1 μg/mL; Abcam, Cambridge, MA, USA), and GAPDH (1:10000, Abcam, Cambridge, MA, USA) were used for Western blot analysis. Band intensities were quantified by Image-Pro Plus 6.0 software. The number of animals used for Western blot was n = 5 for each group.
Statistical analysis
The data was represented as the mean ± SEM. Differences in the means among the groups were statistically analyzed by analysis of variance (ANOVA) with a post hoc Bonferroni's multiple comparisons test. Student's independent t-test was used for comparisons between groups. If normality were not assumed, the comparison between group would be done using a Mann-Whitney U test as non-parametric replacement. Statistical significance was defined at p < 0.05. A post-hoc statistical power estimation was conducted using software G*Power version 3.1 (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, German).
Results
BM-MSCs modulated iNOS expression in LPS-activated microglias in vitro
CD200 is an immunomodulatory marker on the BM-MSCs which conferred immunomodulatory properties (Najar et al., 2012; Zhao et al., 2017) . Hence, we assessed the levels of CD200 expression in BM-MSCs. Immunofluorescence for CD200 showed that the percentage of CD200-expressing BM-MSCs was significantly lower in the BM-MSC group than in the BM-MSC + neural induction group (Fig. 1a, b , 60.80% ± 3.79% vs. 89.60% ± 1.89%, p < 0.01).
Since BM-MSCs expressed CD200, we addressed if BM-MSCs possess immunomodulatory properties in vitro. Inducible nitric oxide synthase (iNOS) is an inflammatory enzyme in microglias responses to inflammatory stimuli (Sierra et al., 2014; Jose et al., 2014) . As shown in Fig. 1c , LPS treatment significantly increased iNOS expression in the microglial cells. However, co-culture with BM-MSCs significantly reduced LPS-induced iNOS expression in the microglial cells ( Fig. 1c and  d , p < 0.01). This result indicated that BM-MSCs possessed in vitro immunomodulatory properties in regulating the LPS-induced microglial activation.
BM-MSC transplantation induced microglial inactivation
To evaluate the in vivo effect of BM-MSCs on microglia, a MCAO rat model was established. At 3 days after intravenous injection into MCAO rats, BM-MSCs could be observed in the peri-infarct area but not in the CA1 of MCAO rats (Fig. 2) , indicating the injected BM-MSCs can migrate to the peri-infarct area.
We then investigated whether the transplanted BM-MSCs can confer neuroimmune modulation in vivo. To evaluate microglial activation in the peri-infarct and CA1 regions, immunofluorescence staining for IBA-1 (a marker of activated microglia) was performed. As shown in Fig. 2a , the activated microglias in the peri-infarct area in the control group exhibited irregular and amoeba-like characteristics, whereas those in the transplant group were smaller and irregular in shape (Fig. 3a) . IBA-1 immunofluorescence showed that BM-MSC transplantation significantly reduced the IBA-expressing microglial cells in the peri-infarct area as compared with the control group ( Fig. 3a and b, p < 0.01) . Notably, we found that prior injection of CD200R1 neutralizing antibody significantly attenuated the BM-MSC-induced decrease in IBAexpressing microglial cells (Fig. 3b , p < 0.01).
There were 3-7 cells /field activated microglias in the CA1 region ( Fig. 3c ), but no difference was found between the transplant group and control group (Fig. 3d, p > 0.05) .
Consistently, Western blot demonstrated that IBA-1 expression in the peri-infarct area was significantly reduced in the transplant group as compared with the control group (Fig. 3e, 3f , p < 0.01). However, prior injection of CD200R1 neutralizing antibody significantly restored IBA expression at 3 days post-BM-MSC transplantation (Fig. 3e, f , p < 0.01). These results suggested that the transplanted BM-MSCs possessed in vivo neuroimmune modulatory potential by inactivating the microglia, which can be counteracted by delivering CD200R1 neutralizing antibody in the peri-infarct prior to BM-MSC transplantation.
BM-MSC transplantation reduce the volume of the infarct zone
The therapeutic efficacy of transplanted BM-MSCs was evaluated by TTC staining (Fig. 4b) . The percentage of infarct zone was significantly lower in the transplant group than in the control group (Fig. 4c , p < 0.01). There was no significant difference between the transplant + CD200R Ab group and the transplant group (Fig. 4c , p > 0.05). These results suggest that transplanted BM-MSCs can significantly reduce the volume of the infarct zone, and CD200R1 Ab injection in the peri-infarct area cannot counteract the therapeutic effects of BM-MSC transplantation.
An overall estimation of statistical power among three groups was 61.20% (one-way ANOVA) where the effect size (eta-square = 0.74) was large.
BM-MSC transplantation protected neuron from apoptosis in the periinfarct and CA1 regions
To determine whether the activated microglias are accompanied by neuron apoptosis in the peri-infarct, we addressed neuronal apoptosis by TUNEL assay. The result revealed that the transplant group had fewer TUNEL-positive cells in the peri-infarct area than the control group (Fig. 4d , e, p < 0.01), indicating the neuroprotective effect of BM-MSC transplantation in the peri-infarct area. Meanwhile, there were significantly more TUNEL-positive cells in the peri-infarct area in the transplant + CD200R Ab group than in the transplant group (Fig. 4e , p < 0.01), indicating that the neuroprotective effect of BM-MSC transplantation was partially counteracted by the CD200R1 neutralizing antibody. There was also a significant difference in the TUNELpositive cells in the CA1 region between groups (Fig. 4f, g, p < 0.01) .
The estimation of statistical power between groups was almost 100% (t-test) where the effect size (d = 6.27) was extremely large.
BM-MSC transplantation effectively protected neuronal degeneration in the peri-infarct area in the acute phase of brain ischemia
CD200 is a glycoprotein primarily expressed by neurons and microglias when inflammatory responses occur in the brain (Shrivastava et al., 2012; McGuckin et al., 2013) . Previous study has shown that in the acute phase of brain ischemia, neuronal CD200 expression is markedly decreased in the brain due to the degeneration of CD200expressing cells (Matsumoto et al., 2007; Sierra et al., 2014) . However, CD200 levels is increased at 5 days after brain ischemia (Zanier et al., 2014; Pietila et al., 2012; Matsumoto et al., 2007; Sierra et al., 2014; Zhao et al., 2017) . The time point of our study was 2 days and 3 days post-infarct, which is prior to the increase in the microglias expressing CD200 at 5 days after brain ischemia.
Double fluorescence (CM-Dil/CD200) staining assay demonstrated that there were CD200-expressing transplanted BM-MSCs in the periinfarct area (Fig. 5a ). Neuronal CD200 expression was detected by NeuN/CD200 double immunofluorescence.BM-MSCs (1 × 10 6 cells in 200 μL) without CM-Dil stained were transplanted in the transplant group. There was more neuronal CD200 expression in the peri-infarct area in the transplant group than in the control group (Fig. 5b , p < 0.01).
Moreover, Western blot showed that the expression of CD200 in the peri-infarct area was significantly higher in transplant group than in the control group at both 2 days and 3 days post-transplantation ( Fig. 6 , p < 0.01). These results indicated that BM-MSC transplantation effectively protected neuronal degeneration in the acute phase of brain ischemia.
The estimations of statistical power between/within groups and of their interaction were all over 99% (two-way mixed design ANOVA) where the effect sizes (partial eta-squares of between, within, and interaction effect were 0.996, 0.975, and 0.949, respectively) were all extremely large.
Discussion
In this study, we investigated the immunomodulatory effect of BM-MSCs on the regulation of microglial inactivation in the acute phase of stroke in MCAO rat. In vitro study showed that co-culture with BM-MSCs significantly reduced LPS-induced iNOS expression in the microglial cells. Immunofluorescence and Western blot consistently revealed that BM-MSC transplantation significantly reduced the IBA-expressing microglial cells and IBA protein levels in the peri-infarct area. The inhibitory effect of BM-MSC on IBA expression was significantly attenuated by prior injection of CD200R1 neutralizing antibody into the peri-infarct area. BM-MSC transplantation significantly reduced the infarct volume, protected neuron apoptosis, increased neuronal CD200 Fig. 2 . Transplanted BM-MSCs migrated to the peri-infarct area (scale bars, 50 μm). Initially, 1 × 10 6 MSCs were intravenously injected into the MCAO rats at 12 h after ischemia. At 3 days after intravenous injection into MCAO rats, CM-DiI-stained BM-MSCs (red arrow) with DAPI for nuclear staining (blue arrow) were found in the peri-infarct area but not the CA1 region. expression in the peri-infarct and CA1 regions. Taken together, these results suggested that the transplanted BM-MSCs possessed neuroimmune modulatory effect by inactivating the microglias in vivo, at least partially, via CD200-CD200R1 signaling.
We found that intravenous transplantation of BM-MSCs reduced the number of IBA-1-expressing microglias and IBA-1 protein expression in the peri-infarct area, suggesting that BM-MSCs can inactivate microglia. This result is in line with the study on MSCs delivery to the cortex near the ischemic striatum (Zhao et al., 2017; McGuckin et al., 2013; Lim et al., 2015) . However, we found that BM-MSCs transplantation did not significantly affect activated microglias in the CA1 region, indicating that the transplanted BM-MSCs can migrate to the peri-infarct area but not the CA1 region. These findings also indicated that the intravenously transplanted BM-MSCs mainly exerted their immunomodulatory effects in the peri-infarct area.
CD200 is a glycoprotein with a broad expression pattern and has been suggested as an immunomodulatory marker of the native MSC population ( et al., 2017) . Our study showed that 60.80% BM-MSCs and 89.60% of BM-MSC with neural induction were positive for CD200 (Shrivastava et al., 2012) . The CD200-expressing BM-MSCs were observed in the peri-infarct area, indicating that the immunomodulation effect of transplanted BM-MSCs was primarily functioned in the peri-infarct area. Our result revealed the immunomodulatory effect of BM-MSCs on microglial inactivation was attenuated by CD200R1 Ab pretreatment, suggesting that BM-MSCs inhibited microglias activation via CD200- CD200R1 interaction, which is essential for the immunomodulatory properties of for BM-MSCs. On the other hand, CD200-CD200R1 interaction is also crucial for the microglia-neuron crosstalk in regulating the activation of microglias (Matsumoto et al., 2007) . During ischemic stroke, CD200 expression by neurons is decreased, and the CD200-CD200R1 association is interrupted, triggering microglial activation. Our results showed that BM-MSCs transplantation increased CD200expressing neurons in the peri-infarct area, which may be attributed to the neurotrophic effects of the transplanted BM-MSCs. Consist with our findings, Kong et al. recently reported that transplantation of CD200positive human placenta-derived stem cells into the ischemic rat model of stroke significantly downregulated pro-inflammatory cytokines, upregulated CD200 and inhibited microglias activation (Hernangómez et al., 2016) .
Our result showed that BM-MSCs transplantation significantly reduced the infarct volume. It has been suggested that the neuroprotective effect of MSCs in CA1 region during the acute phase of stroke is more likely due to the neurotrophic effects of the transplanted MSCs rather than the immunomodulatory properties (Hernangómez et al., 2016; Satani and Savitz, 2016; Jeong et al., 2014) . Supporting this notion, we observed that the prior injection of CD200R1 neutralizing antibody did not affect the neuroprotective effects of BM-MSCs transplantation on the infarct volume.
In this study, we demonstrated the immunomodulatory effect of BM-MSCs on the regulation of brain microglial inactivation during the acute phase of stroke. However, the effect of BM-MSCs in chronic phase of stroke remains to be investigated.
In conclusion, our results showed that intravenously transplanted BM-MSCs exerted in vivo immunomodulatory capacity by inactivating microglias in the peri-infarct area, at least partially, via CD200-CD200R1 signaling. Our findings are helpful for better understanding of the molecular mechanism of immunomodulatory properties of BM-MSCs. (a) The CD200 expression in the transplanted BM-MSCs in the peri-infarct area was evaluated by immunofluorescence staining. The red arrow indicated the DiIlabeled BM-MSCs, the green arrow indicated the CD200-expressing cell, and the yellow arrow indicated CD200-expressing transplanted BM-MSCs. (b) Neuronal CD200 expression in the peri-infarct area was shown at different magnifications (scale bars, 100 μm and 25 μm). The red arrow indicated the NeuN-expressing cell, the green arrow indicated the CD200-expressing cell, and the yellow arrow indicated the neuronal CD200 cells. The plot showed quantitative comparison of neuronal CD200 expression in the peri-infarct between the transplant and control group. **, p < 0.01. 
